Biogen Idec’s Zevalin Brochure Misleading, DDMAC Says

Drug Industry Daily
KEYWORDS Advertising / FDA
A A

The FDA has cited Biogen Idec for disseminating a promotional brochure that fails to present important risk information about its cancer drug Zevalin.

To View This Article:

Login

Subscribe To Drug Industry Daily